A new agent for the treatment of lung cancer: B13 loaded solid lipid nanoparticles

Lung cancer is the leading cause of cancer-related deaths in humans. Recently, the effects of nano-carriers as chemotherapeutic agents on the treatment of lung cancer are in the main focus of cancer research. The use of solid lipid nanoparticles (SLNs) promises high hopes in treatment with the advantages of providing drug localisation in terms of action by both passive and active targeting based on their unique properties, including hydrophilic or hydrophobic loads. SLNs open new limits for long-term and side-specific drug delivery. In this study, a novel SLN of the ceramidase inhibitor, B13 (D-NMAPPD), with modified targeting property was designed, synthesised, and evaluated as potential anticancer agent on human lung cancer cells. Our results implied the efficiency of newly synthesised SLNs on lung cancer in the manner of anti-cancer activity with high cytotoxicity on cancer cells.